Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Later lines of systemic therapy in patients with metastatic colorectal cancer: real-world data from a setting with barriers to access cancer therapies.
Jácome AA, Mathias-Machado MC, Gil M, Passarini TM, Cristofaro S, Moraes ED, Freitas LVW, Prolla G, Amorim LC, Paes RD, Gasparotto B, Canedo J, Ferreira CG, Ferrari B, Garicochea B, Gil R, Peixoto RD. Jácome AA, et al. Among authors: ferreira cg. J Gastrointest Oncol. 2024 Dec 31;15(6):2543-2551. doi: 10.21037/jgo-24-524. Epub 2024 Dec 28. J Gastrointest Oncol. 2024. PMID: 39816030 Free PMC article.
Real-World Study on Implementation of Genomic Tests for Advanced Lung Adenocarcinoma in Brazil.
Dienstmann R, da Silva LM, Orpinelli Ramos do Rego F, Muniz Rodrigues A, Koyama FC, Galindo LT, de Bustamante Fernandes C, de Souza BB, Paes RD, Montella T, de Marchi P, Jeha Araújo B, Ferrari BL, Mathias C, Pereira E, Zalis MG, Leslin C, Ferreira CG. Dienstmann R, et al. Among authors: ferreira cg. JCO Glob Oncol. 2024 Nov;10:e2400354. doi: 10.1200/GO-24-00354. Epub 2024 Nov 21. JCO Glob Oncol. 2024. PMID: 39571128
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.
Felip E, Cho BC, Gutiérrez V, Alip A, Besse B, Lu S, Spira AI, Girard N, Califano R, Gadgeel SM, Yang JC, Yamamoto S, Azuma K, Kim YJ, Lee KH, Danchaivijitr P, Ferreira CG, Cheng Y, Sendur MAN, Chang GC, Wang CC, Prabhash K, Shinno Y, Stroyakovskiy D, Paz-Ares L, Rodriguez-Cid JR, Martin C, Campelo MRG, Hayashi H, Nguyen D, Tomasini P, Gottfried M, Dooms C, Passaro A, Schuler M, Gelatti ACZ, Owen S, Perdrizet K, Ou SI, Curtin JC, Zhang J, Gormley M, Sun T, Panchal A, Ennis M, Fennema E, Daksh M, Sethi S, Bauml JM, Lee SH. Felip E, et al. Among authors: ferreira cg. Ann Oncol. 2024 Sep;35(9):805-816. doi: 10.1016/j.annonc.2024.05.541. Epub 2024 Jun 26. Ann Oncol. 2024. PMID: 38942080 Free article. Clinical Trial.
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Besse B, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yoshioka H, Yang JC, Thomas M, Nguyen D, Ou SI, Mukhedkar S, Prabhash K, D'Arcangelo M, Alatorre-Alexander J, Vázquez Limón JC, Alves S, Stroyakovskiy D, Peregudova M, Şendur MAN, Yazici O, Califano R, Gutiérrez Calderón V, de Marinis F, Passaro A, Kim SW, Gadgeel SM, Xie J, Sun T, Martinez M, Ennis M, Fennema E, Daksh M, Millington D, Leconte I, Iwasawa R, Lorenzini P, Baig M, Shah S, Bauml JM, Shreeve SM, Sethi S, Knoblauch RE, Hayashi H; MARIPOSA Investigators. Cho BC, et al. N Engl J Med. 2024 Oct 24;391(16):1486-1498. doi: 10.1056/NEJMoa2403614. Epub 2024 Jun 26. N Engl J Med. 2024. PMID: 38924756 Clinical Trial.
169 results